Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioXell S.p.A.
After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
A total of six medicines were recommended for use on the National Health Service in Scotland in August.
Proposed reimbursement decision to be released by 12 January 2022, with a final decision the following April. Biogen's Aduhelm expected to be covered in the interim. Medicare will not consider the cost of treatment in the analysis, but cost may have been a factor in initiating the process.